A contract with Zoll will offer the Vizient Inc healthcare systems access to the TherOx Supersaturated Oxygen Therapy, which can benefit patients facing the most lethal of heart attacks, the LAD-STEMI.

RT’s Three Key Takeaways

  1. Zoll received an Innovative Technology contract from Vizient Inc, recognizing its potential to enhance cardiovascular care through its unique SSO2 Therapy.
  2. SSO2 Therapy, FDA-approved and clinically proven, significantly reduces cardiac muscle damage in LAD STEMI heart attack patients following coronary angioplasty and stenting.
  3. Vizient awarded the contract based on expert recommendations, highlighting the therapy’s potential to improve patient outcomes and hospital operations.

Zoll received an innovative technology contract from Vizient Inc, the nation’s largest provider-driven healthcare performance improvement company. The contract was awarded based on the recommendation of hospital experts who serve on one of Vizient’s customer-led councils, and it signifies unique qualities that potentially bring improvement to patient cardiovascular care.

Innovative Technology contracts are recommended after review and interaction with products submitted through Vizient’s Innovative Technology Program. Vizient customer-led councils identify technologies that have the potential to enhance clinical care, patient safety, healthcare worker safety, or improve business operations of healthcare organizations.

“Each year, more than 258,000 patients in the US access emergency rooms as a result of heart attacks,” said Matt Rochner, TherOx General Manager. “SSO2 therapy can benefit patients facing the most lethal of heart attacks, the LAD-STEMI. Zoll is very pleased to work with Vizient to offer this new, innovative technology to Vizient customer hospitals.”

Patients with left anterior descending ST-elevation myocardial infarction (LAD STEMI) heart attacks have higher mortality rates than other types of heart attacks. SSO2 Therapy is the first and only FDA-approved treatment that has been clinically proven to significantly reduce damage to cardiac muscle in heart attack patients after coronary angioplasty with stenting. The extent of damaged cardiac muscle is a strong predictor of future outcomes like rehospitalization and the development of heart failure.

SSO2 Therapy is indicated for patients who suffer a LAD STEMI — also known as “widowmaker” heart attacks due to the high mortality rate — and are treated with stenting within six hours of symptom onset. The therapy delivers high levels of dissolved oxygen at 7–10 times the normal amount directly to the damaged heart muscle immediately after the coronary artery has been successfully opened via angioplasty and stenting. Multiple clinical trials have demonstrated the safety and efficacy of SSO2 Therapy to reduce infarct size.

“A product receives this type of contract when it demonstrates a unique quality that differentiates it from other products on the market,” said Kelly Flaharty, senior director of contract services for Vizient. “Our customer-led council determined that TherOx SuperSaturated Oxygen (SSO2) Therapy met this standard and recognizes its potential to improve quality outcomes.”

References

1 Ahuja KR, Saad AM, Nazir S, Ariss RW, Shekhar S, Isogai T, Kassis N, Mahmood A, Sheikh M, Kapadia SR. Trends in Clinical Characteristics and Outcomes in ST-Elevation Myocardial Infarction Hospitalizations in the United States, 2002-2016. Curr Probl Cardiol. 2022 Dec;47(12):101005. doi: 10.1016/j.cpcardiol.2021.101005. Epub 2021 Oct 7. PMID: 34627825.
2 What is a STEMI Heart Attack? (clevelandclinic.org)
3 Stone GW, et al. Circ Cardiovasc Intervent 2009;2:366-75.
4 Stone GW et al. J Am Coll Cardiol. 2016;67(14):1674–83.
5 O’Neill WW, et al. Jour of Am Coll Cardiol. 2007;50: 5:397-405.
6 David SW, et al. Catheter Cardiovasc Interv. 2018;1–9.
7 https://www.cms.gov/Medicare/Coding/ICD10/Downloads/2020-ICD-10-PCS-Guidelines.pdf
8 Chen S, et al. Catheter Cardiovasc Interv. 2020; 1–7.